-

iXCells Biotechnologies Expands Operations; New Website Goes Live

Increased operational capacity positions company for continued growth; new website offers Users a plethora of enhanced features and benefits

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company specializing in providing cell-based products and drug discovery solutions to the global academic, biotech and pharmaceutical communities, today announced completing key growth initiatives.

The company relocated to new expanded facilities in San Diego, California in July, tripling its footprint for cell product manufacturing, research, and drug discovery services, including tailored production of disease relevant cell models using CRISPR Cas9. iXCells’ chief executive, Dr. Lynn Zhang, commented, “We quickly outgrew our previous space after only a few years and this new facility offers substantially more capacity for scaling production and lab service projects integral to our customers’ preclinical development workflows.”

Dr. Nianwei Lin, the company’s President, added, “This effort is the culmination of almost twelve months of careful planning. I’m immensely proud of all our employees and their contributions in making this relocation highly successful while ensuring minimal interruption to our customer service level. To celebrate this important milestone, we’re planning to announce an exciting open-house event for our customers and suppliers later this year.”

Also in July, the company officially launched its new website, www.ixcellsbiotech.com. iXCells’ Marketing Manager, Luana Meira Williams, commented, “Our new site dramatically increases User experience from product & service browsing through to cart checkout according to UX design best practice. Some of the new features worth mentioning include a powerful global search capability, dynamic product and cell images, related product recommendations, and introduction of a customer referral and loyalty program. Moreover, we incorporated best practice content management systems integrated with our ERP system and marketing automation to deliver optimal functionality and User engagement; we believe customers, business partners, and other Users will be pleased with these new features and benefits.”

About iXCells Biotechnologies

Founded in 2014 and based in San Diego, CA, iXCells Biotechnologies is an innovative cell biology and cell technology company that provides preclinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate the pace of drug discovery. iXCells offers customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and drug screening. To learn more about this innovative leader within the preclinical iPSC sector, visit www.ixcellsbiotech.com.

Follow iXCells Biotechnologies on LinkedIn, Twitter, and on YouTube.

Contacts

Wayne E. Vaz
Corporate Development & Commercial Operations
wayne.vaz@ixcellsbiotech.com

iXCells Biotechnologies USA, Inc.


Release Versions

Contacts

Wayne E. Vaz
Corporate Development & Commercial Operations
wayne.vaz@ixcellsbiotech.com

Social Media Profiles
More News From iXCells Biotechnologies USA, Inc.

iXCells Biotechnologies Launches iPSCore™ Platform for Generating Highly Characterized iPSC-derived Human Cell Models

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform. iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell engineering platform iPSCore™ is a unified and dedicated sy...

iXCells Biotechnologies Announces Grand Opening and 2024 Rare Disease Month Workshop

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company providing innovative cell products and preclinical drug development services to the global academic, biotech, pharmaceutical, and rare disease communities today announced the grand opening celebration of its new San Diego headquarters and Rare Disease Month Workshop. A ribbon-cutting ceremony scheduled February 8th at 9am marks a milestone in the company’s growth, the grand opening of its new fa...

iXCells Biotechnologies Strengthens Leadership Team; Welcomes New CEO

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company specializing in providing cell-based products and drug discovery service solutions to the global academic, biotech, pharmaceutical, and rare disease communities, today announced the appointment of Helge Bastian, PhD, as the company’s new Chief Executive Officer. The company’s co-founder and former CEO, Lynn Zhang, commented, “iXCells has undergone a remarkable transformation over the past few ye...
Back to Newsroom